首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL17F |
| Uniprot No | Q96PD4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-163aa |
| 氨基酸序列 | RKIPKVGHTF FQKPESCPPV PGGSMKLDIG IINENQRVSM SRNIESRSTS PWNYTVTWDP NRYPSEVVQA QCRNLGCINA QGKEDISMNS VPIQQETLVV RRKHQGCSVS FQLEKVLVTV GCTCVTPVIH HVQ |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于IL-17F重组蛋白的关键文献摘要：
---
1. **文献名称**: *"IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding"*
**作者**: Hymowitz SG et al.
**摘要**: 该研究解析了IL-17F与IL-17A的结构相似性，发现两者均具有胱氨酸结(cystine knot)结构，并推测其通过同源或异源二聚体形式结合受体，为后续重组蛋白的功能研究奠定基础。
---
2. **文献名称**: *"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses"*
**作者**: Ishigame H et al.
**摘要**: 通过重组IL-17F蛋白的体内实验，发现IL-17F在黏膜细菌感染中增强中性粒细胞招募，但其促炎作用弱于IL-17A，提示两者在宿主防御和炎症反应中的功能差异。
---
3. **文献名称**: *"Expression, purification, and functional characterization of recombinant human IL-17F in Escherichia coli"*
**作者**: Chen X et al.
**摘要**: 报道了一种高效的大肠杆菌表达系统，成功制备具有生物活性的重组人IL-17F蛋白，并通过体外细胞实验证实其诱导CXCL1等炎症因子分泌的能力。
---
4. **文献名称**: *"IL-17F signaling requires ubiquitination of its receptor IL-17RC through TRAF6"*
**作者**: Zhang B et al.
**摘要**: 利用重组IL-17F蛋白揭示其受体IL-17RC的信号传导机制，证明TRAF6介导的泛素化修饰对下游NF-κB通路激活至关重要，为靶向IL-17F的炎症性疾病治疗提供理论依据。
---
**备注**：上述文献涵盖IL-17F的结构解析、功能差异、重组制备方法及信号机制研究，适用于基础研究和药物开发参考。如需具体期刊信息或年份，可进一步补充筛选条件。
Interleukin-17F (IL-17F) is a pro-inflammatory cytokine belonging to the IL-17 family, which comprises six members (IL-17A to IL-17F). It shares structural homology (~50% amino acid identity) and functional overlap with IL-17A, the most studied member. Both cytokines are primarily produced by Th17 cells, γδ T cells, and innate lymphoid cells, playing critical roles in host defense against extracellular pathogens and in the pathogenesis of autoimmune and chronic inflammatory diseases, such as psoriasis, rheumatoid arthritis, and asthma. IL-17F signals through the IL-17 receptor complex (IL-17RA/IL-17RC), activating downstream pathways like NF-κB and MAPK, leading to the production of inflammatory mediators (e.g., IL-6. TNF-α, and antimicrobial peptides).
Recombinant IL-17F protein is generated using biotechnological platforms (e.g., Escherichia coli or mammalian expression systems) to produce a purified, bioactive form for research and therapeutic exploration. Its recombinant form allows precise study of IL-17F-specific functions, distinct from IL-17A, including its weaker inflammatory potency and unique contributions to mucosal immunity and tissue homeostasis. Studies suggest IL-17F may have dual roles—exacerbating inflammation in diseases like asthma while exhibiting protective effects in gut barrier integrity.
The development of IL-17F-targeted therapies, including monoclonal antibodies or small-molecule inhibitors, has gained interest due to its potential for reduced immunosuppressive risks compared to IL-17A blockade. Recombinant IL-17F also serves as a tool for elucidating signaling mechanisms, screening therapeutic agents, and modeling disease in vitro or in vivo. However, its clinical relevance and therapeutic targeting remain under investigation, necessitating further research to clarify its context-dependent roles in immunity and pathology.
×
